Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10253473 | 0.86 | CHEK1 (0.38) | CHEK1PDK2PDK4 | |
| SCHEMBL645961 | 0.83 | CHEK1 (0.36) | CHEK1PDK2PDK4 | |
| SCHEMBL2612692 | 0.76 | PDK2 (0.37) | CHEK1PDK2PDK4GSK3AGSK3B | |
| SCHEMBL4415500 | 0.74 | CHUK (0.51) | CHEK1PDK2PDK4GSK3B | |
| SCHEMBL644707 | 0.74 | ATM (0.41) | — | |
| SCHEMBL2620673 | 0.74 | METAP2 (0.39) | CHEK1PDK2PDK4 | |
| SCHEMBL13598849 | 0.72 | PDK2 (0.41) | CHEK1PDK2PDK4GSK3AGSK3B | |
| SCHEMBL12969458 | 0.71 | PDK2 (0.35) | PDK2PDK4 | |
| SCHEMBL4421034 | 0.71 | PDK2 (0.43) | CHEK1PDK2PDK4 | |
| SCHEMBL4423714 | 0.69 | PDK2 (0.37) | CHEK1PDK2PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | claimed |
| EP-1931669-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | claimed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| US-8318939-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-2145877-B1 | Aurora Kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2012-10-03 | — | — | EP | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| EP-2081930-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1931669-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008054956-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | TTR 4619/4885ALB 3943/4885CHEK1 57/4885 |
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | TTR 4791/4885ALB 4671/4885CHEK1 52/4885 |
| US-20100190816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | TTR 4619/4885ALB 3943/4885CHEK1 57/4885 |
| US-20120252761-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | TTR 4791/4885ALB 4671/4885CHEK1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.